Staging lung carcinoma with a Tc-99m labeled monoclonal antibody

J. P. Vansant, D. H. Johnson, D. M. O'Donnell, J. R. Stewart, A. H. Sonin, B. M. McCook, T. A. Powers, D. J. Salk, W. H. Frist, M. P. Sandler

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Thirty-three patients with biopsy-proven lung cancer and a total of 150 lesions diagnosed by conventional staging procedures were imaged using a Tc- 99m labeled monoclonal Fab fragment of an IgG2B murine monoclonal antibody (MoAb) (NR-LU-10, NeoRx Corporation). Immunoscintigraphy demonstrated 100% of primary and 78% of metastatic lesions. MoAb imaging detected 88% of lesions in 12 small cell lung cancer (SCLC) patients and 77% of lesions in 21 non- small cell lung cancer (NSCLC) patients. Based on initial evaluation by other methods, 29 sites of MoAb activity were not associated with evidence of disease. Eleven of these were subsequently shown to represent sites of metastases; 18 remain unconfirmed. Four of ten patients studied with limited NSCLC had eight unsuspected lesions on MoAb imaging. Confirmation of unsuspected lesions in two patients altered initial clinical staging, and surgical therapy was abandoned. This study demonstrates that Tc-99m labeled NR-LU-10 can accurately stage patients with lung cancer.

Original languageEnglish (US)
Pages (from-to)431-438
Number of pages8
JournalClinical Nuclear Medicine
Volume17
Issue number6
StatePublished - 1992

Fingerprint

Monoclonal Antibodies
Carcinoma
Lung
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Immunoglobulin Fab Fragments
Small Cell Lung Carcinoma
Immunoglobulin G
Neoplasm Metastasis
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Vansant, J. P., Johnson, D. H., O'Donnell, D. M., Stewart, J. R., Sonin, A. H., McCook, B. M., ... Sandler, M. P. (1992). Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clinical Nuclear Medicine, 17(6), 431-438.

Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. / Vansant, J. P.; Johnson, D. H.; O'Donnell, D. M.; Stewart, J. R.; Sonin, A. H.; McCook, B. M.; Powers, T. A.; Salk, D. J.; Frist, W. H.; Sandler, M. P.

In: Clinical Nuclear Medicine, Vol. 17, No. 6, 1992, p. 431-438.

Research output: Contribution to journalArticle

Vansant, JP, Johnson, DH, O'Donnell, DM, Stewart, JR, Sonin, AH, McCook, BM, Powers, TA, Salk, DJ, Frist, WH & Sandler, MP 1992, 'Staging lung carcinoma with a Tc-99m labeled monoclonal antibody', Clinical Nuclear Medicine, vol. 17, no. 6, pp. 431-438.
Vansant JP, Johnson DH, O'Donnell DM, Stewart JR, Sonin AH, McCook BM et al. Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clinical Nuclear Medicine. 1992;17(6):431-438.
Vansant, J. P. ; Johnson, D. H. ; O'Donnell, D. M. ; Stewart, J. R. ; Sonin, A. H. ; McCook, B. M. ; Powers, T. A. ; Salk, D. J. ; Frist, W. H. ; Sandler, M. P. / Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. In: Clinical Nuclear Medicine. 1992 ; Vol. 17, No. 6. pp. 431-438.
@article{2838b4ddcc42473cb0c1fda1bc5a4033,
title = "Staging lung carcinoma with a Tc-99m labeled monoclonal antibody",
abstract = "Thirty-three patients with biopsy-proven lung cancer and a total of 150 lesions diagnosed by conventional staging procedures were imaged using a Tc- 99m labeled monoclonal Fab fragment of an IgG2B murine monoclonal antibody (MoAb) (NR-LU-10, NeoRx Corporation). Immunoscintigraphy demonstrated 100{\%} of primary and 78{\%} of metastatic lesions. MoAb imaging detected 88{\%} of lesions in 12 small cell lung cancer (SCLC) patients and 77{\%} of lesions in 21 non- small cell lung cancer (NSCLC) patients. Based on initial evaluation by other methods, 29 sites of MoAb activity were not associated with evidence of disease. Eleven of these were subsequently shown to represent sites of metastases; 18 remain unconfirmed. Four of ten patients studied with limited NSCLC had eight unsuspected lesions on MoAb imaging. Confirmation of unsuspected lesions in two patients altered initial clinical staging, and surgical therapy was abandoned. This study demonstrates that Tc-99m labeled NR-LU-10 can accurately stage patients with lung cancer.",
author = "Vansant, {J. P.} and Johnson, {D. H.} and O'Donnell, {D. M.} and Stewart, {J. R.} and Sonin, {A. H.} and McCook, {B. M.} and Powers, {T. A.} and Salk, {D. J.} and Frist, {W. H.} and Sandler, {M. P.}",
year = "1992",
language = "English (US)",
volume = "17",
pages = "431--438",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Staging lung carcinoma with a Tc-99m labeled monoclonal antibody

AU - Vansant, J. P.

AU - Johnson, D. H.

AU - O'Donnell, D. M.

AU - Stewart, J. R.

AU - Sonin, A. H.

AU - McCook, B. M.

AU - Powers, T. A.

AU - Salk, D. J.

AU - Frist, W. H.

AU - Sandler, M. P.

PY - 1992

Y1 - 1992

N2 - Thirty-three patients with biopsy-proven lung cancer and a total of 150 lesions diagnosed by conventional staging procedures were imaged using a Tc- 99m labeled monoclonal Fab fragment of an IgG2B murine monoclonal antibody (MoAb) (NR-LU-10, NeoRx Corporation). Immunoscintigraphy demonstrated 100% of primary and 78% of metastatic lesions. MoAb imaging detected 88% of lesions in 12 small cell lung cancer (SCLC) patients and 77% of lesions in 21 non- small cell lung cancer (NSCLC) patients. Based on initial evaluation by other methods, 29 sites of MoAb activity were not associated with evidence of disease. Eleven of these were subsequently shown to represent sites of metastases; 18 remain unconfirmed. Four of ten patients studied with limited NSCLC had eight unsuspected lesions on MoAb imaging. Confirmation of unsuspected lesions in two patients altered initial clinical staging, and surgical therapy was abandoned. This study demonstrates that Tc-99m labeled NR-LU-10 can accurately stage patients with lung cancer.

AB - Thirty-three patients with biopsy-proven lung cancer and a total of 150 lesions diagnosed by conventional staging procedures were imaged using a Tc- 99m labeled monoclonal Fab fragment of an IgG2B murine monoclonal antibody (MoAb) (NR-LU-10, NeoRx Corporation). Immunoscintigraphy demonstrated 100% of primary and 78% of metastatic lesions. MoAb imaging detected 88% of lesions in 12 small cell lung cancer (SCLC) patients and 77% of lesions in 21 non- small cell lung cancer (NSCLC) patients. Based on initial evaluation by other methods, 29 sites of MoAb activity were not associated with evidence of disease. Eleven of these were subsequently shown to represent sites of metastases; 18 remain unconfirmed. Four of ten patients studied with limited NSCLC had eight unsuspected lesions on MoAb imaging. Confirmation of unsuspected lesions in two patients altered initial clinical staging, and surgical therapy was abandoned. This study demonstrates that Tc-99m labeled NR-LU-10 can accurately stage patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026650505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026650505&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 431

EP - 438

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 6

ER -